TOMM5

Across TCGA pan-cancer cohorts, TOMM5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TOMM5 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TOMM5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TOMM5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where TOMM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.451	1.000	.016	22	view →
LSCC	DFS	Quartile	III,IV	1.000	0.330	.016	10	view →
LUAD	DFS	Quartile	II,III,IV	1.000	0.793	.002	5	view →
PDAC	DFS	Median	All	0.717	0.868	.028	2	view →
HNSC	DFS	Median	III,IV	0.913	0.992	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TOMM5–CCRCC (OS)

Open the CCRCC breakdown →